Please select the option that best describes you:
Will you be changing your management of locally advanced cervical cancer based on the results of the INTERLACE trial presented at ESMO 2023?
The trial showed an overall survival benefit of 8% at 5 years with induction chemotherapy (80% vs 72%) utilizing at least 5 cycles of carboplatin-paclitaxel vs standard treatment.
Answer from: Radiation Oncologist at Academic Institution
Absolutely NOT. INTERLACE results are in abstract form only, including early-stage disease I-II at 86%, and the details regarding radiation are minimal, stating it's prescribed to point A and recommend CT/MR planning (we do not know how many patients underwent image-guided brachytherapy).
Also, i...
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
I think it is too early to commit all patients to induction chemo, based on what I know about this study. It is important to review the details of the study, as mentioned by Dr. @Beriwal. In addition, it is important to understand the differences between studies that led to an overall survival benef...
Answer from: Radiation Oncologist at Community Practice
I would wait for the publications for details including brachytherapy and recurrence pattern but could potentially be practice-changing.
Comments
Radiation Oncologist at Allan Blair Cancer Centre
I do wonder in certain cases if it’s possibl...
I do wonder in certain cases if it’s possibl...